胰高血糖素市場 - 按產品類型（注射劑、吸入劑）、應用（低血糖、診斷輔助、胃腸道疾病）、配銷通路（醫院藥房、零售藥房、線上藥房） - 全球預測（2024 - 2032）

由於自我管理設備的蓬勃發展，2024 年至 2032 年間，全球胰高血糖素市場的複合年成長率將超過 5.9%。這些設備易於使用，使患者能夠獨立管理低血糖事件，從而提高便利性和依從性。自我管理的轉變減少了對立即醫療救助的需求，這對於血糖水平突然下降的糖尿病患者特別有益。

2023 年 8 月，Xeris Pharmaceuticals Inc. 報告稱，78% 的商業保險和醫療保險受益人可以不受限制地使用 Gvoke HypoPen，這是一種用於治療嚴重低血糖的胰高血糖素注射劑。直覺且可靠的輸送系統的發展促進了這一趨勢，該系統確保準確的劑量並減少與緊急胰高血糖素使用相關的焦慮。對胰高血糖素產品的需求將大幅增加。

整個胰高血糖素市場根據產品類型、應用、配銷通路和地區進行分類。

從2024年到2032年，吸入劑細分市場將呈現大幅複合年成長率，因為其非侵入性且方便的給藥方式對注射不舒服的患者很有吸引力。吸入胰高血糖素可快速吸收並起效，使其成為低血糖的有效緊急治療方法。此外，它的易用性確保了對傳統注射方法有困難的患者（包括兒童和老年人）更好的依從性。藥物傳遞技術的進步增強了患者體驗和可及性，擴大了吸入領域不斷成長的需求。

到2032 年，診斷輔助領域將佔據重要的胰高血糖素市場佔有率。需求正在增加。胰高血糖素用於放鬆胃腸道平滑肌，促進更清晰的影像結果並有助於診斷準確性。它在暫時抑制胰島素分泌方面的有效性在某些診斷測試中也被證明是有價值的。隨著醫療程序的發展和影像技術的進步，由於胰高血糖素在增強診斷能力和患者護理結果方面的作用，對胰高血糖素作為診斷輔助劑的需求持續成長。

從2024年到2032年，北美胰高血糖素市場將呈現健康的複合年成長率。城市化進程的加速和久坐的生活方式導致糖尿病和相關併發症的盛行率升高，因此需要有效的管理解決方案，例如胰高血糖素。醫療基礎設施的改善和可支配收入的增加正在擴大糖尿病護理產品的取得範圍。旨在提高公眾健康意識和糖尿病管理的政府措施也在刺激市場成長方面發揮著至關重要的作用。這些因素有助於亞太地區對胰高血糖素的需求不斷成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
  • 糖尿病盛行率上升
  • 增加研發活動
  • 對非注射緊急肝醣的需求不斷成長
  • 製藥業的進步
  • 產業陷阱與挑戰
  • 缺乏消費者意識
  • 嚴格的監管框架
• 成長潛力分析
• 監管環境
• 技術景觀
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 競爭定位矩陣
• 公司矩陣分析
• 戰略展望矩陣

第 5 章：市場估計與預測：按產品類型，2021 - 2032 年

• 主要趨勢
• 可注射
• 吸入

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 低血糖
• 診斷輔助
• 胃腸道疾病
• 心臟休克
• 其他應用

第 7 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Amgen Inc.
• Avalon Pharma Private Limited
• Bachem Holding AG
• Eli Lilly and Company
• Fresenius SE & Co. KGaA
• Fujifilm Holdings Corporation
• Novo Nordisk A/S
• Pfizer, Inc.
• Svar Life Science
• Taj Pharmaceuticals Ltd.
• Xeris Biopharma Holdings, Inc.

Global Glucagon Market will exhibit over 5.9% CAGR between 2024 and 2032, catapulted by the thriving adoption of self-administration devices. These devices, designed for ease of use, empower patients to manage hypoglycemic episodes independently, enhancing convenience and compliance. The shift toward self-administration reduces the need for immediate medical assistance, which is particularly beneficial for diabetic patients who experience sudden drops in blood sugar levels.

In August 2023, Xeris Pharmaceuticals Inc. reported that 78% of commercially insured and Medicare beneficiaries had unrestricted access to Gvoke HypoPen, a glucagon injection for severe hypoglycemia treatment. This trend is encouraged by the development of intuitive and reliable delivery systems, which ensure accurate dosing and reduce the anxiety associated with emergency glucagon use. The demand for glucagon products will upsurge significantly.

The overall glucagon market is categorized based on product type, application, distribution channel, and region.

From 2024 to 2032, the inhalation segment will depict substantial CAGR growth due to its non-invasive and convenient delivery method, which is appealing to patients who are uncomfortable with injections. Inhalation glucagon offers rapid absorption and onset of action, making it an effective emergency treatment for hypoglycemia. Additionally, its ease of use ensures better adherence among patients, including children and the elderly, who struggle with traditional injection methods. This advancement in drug delivery technology enhances patient experience and accessibility, amplifying the increasing demand in the inhalation segment.

The diagnostic aid segment will possess a significant glucagon market share by 2032. The demand for glucagon in the diagnostic aid segment is increasing owing to its utility in various medical procedures such as gastrointestinal motility studies and imaging scans. Glucagon is used to relax the smooth muscles of the gastrointestinal tract, facilitating clearer imaging results and aiding in diagnostic accuracy. Its effectiveness in temporarily inhibiting insulin secretion also proves valuable in certain diagnostic tests. As medical procedures evolve and imaging technologies advance, the demand for glucagon as a diagnostic aid continues to grow, directed by its role in enhancing diagnostic capabilities and patient care outcomes.

From 2024 to 2032, North America glucagon market will demonstrate a healthy CAGR. Increasing urbanization and the adoption of a more sedentary lifestyle contribute to a higher prevalence of diabetes and related complications, necessitating effective management solutions such as glucagon. Improving healthcare infrastructure and rising disposable incomes are expanding access to diabetes care products. Government initiatives aimed at improving public health awareness and diabetes management also play a crucial role in stimulating market growth. These factors aid the growing demand for glucagon in the Asia Pacific.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Rising prevalence of diabetes
  • 3.2.3 Increasing research & development activities
  • 3.2.4 Growing demand for non-injectable emergency glycogen
  • 3.2.5 Advancements in pharmaceutical sector
  • 3.2.6 Industry pitfalls & challenges
  • 3.2.7 Lack of consumer awareness
  • 3.2.8 Stringent regulatory framework
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Company matrix analysis
• 4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Inhalation

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypoglycemia
• 6.3 Diagnostic aid
• 6.4 Gastrointestinal disorders
• 6.5 Cardiogenic shock
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Amgen Inc.
• 9.2 Avalon Pharma Private Limited
• 9.3 Bachem Holding AG
• 9.4 Eli Lilly and Company
• 9.5 Fresenius SE & Co. KGaA
• 9.6 Fujifilm Holdings Corporation
• 9.7 Novo Nordisk A/S
• 9.8 Pfizer, Inc.
• 9.9 Svar Life Science
• 9.10 Taj Pharmaceuticals Ltd.
• 9.11 Xeris Biopharma Holdings, Inc.